Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 1:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 3,601 matching trials from the live ClinicalTrials.gov search.
Conditions
Plasma Cell Leukemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, High Throughput Screening, Laboratory Biomarker Analysis
Procedure · Device · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
dexamethasone, lenalidomide, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
2
States / cities
Royal Oak, Michigan • Salt Lake City, Utah
Conditions
Multiple Myeloma
Interventions
High-Dose Melphalan HCL for Injection (Propylene Glycol-Free), Autologous Transplantation
Drug · Other
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
Up to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
Chicago, Illinois • Fairway, Kansas • Worcester, Massachusetts + 3 more
Conditions
Multiple Myeloma
Interventions
HuLuc63
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 5 more
Conditions
Multiple Myeloma, Amyloidosis
Interventions
Tacrolimus, Equine Anti-thymocyte globulin, Kidney transplant from a related donor, Bone marrow transplant from a related donor, Total body irradiation 400 centigray (200 cGy X 2)
Drug · Procedure · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Healthy
Interventions
K0706
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Glendale, California
Conditions
Multiple Myeloma
Interventions
carfilzomib
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
28
States / cities
Mobile, Alabama • Scottsdale, Arizona • Beverly Hills, California + 23 more
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Thalidomide, Cisplatinum, Adriamycin, Cyclophosphamide, Etoposide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
Lenalidomide, nab-paclitaxel
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Not listed
Lead sponsor
Exosome Diagnostics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Hollywood, Florida • New Orleans, Louisiana
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients

NCT00536575
Conditions
Multiple Myeloma
Interventions
Bortezomib, Sorafenib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • Nashville, Tennessee
Conditions
Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Interventions
Manufactured Anti-BCMA CAR-T cells, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
Thomas Martin, MD
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2038
U.S. locations
1
States / cities
San Francisco, California
Conditions
Multiple Myeloma
Interventions
Iberdomide
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
2
States / cities
Omaha, Nebraska • Buffalo, New York
Conditions
Non Hodgkin Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Interventions
JCAR017, JCARH125
Genetic
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Duarte, California • Boston, Massachusetts
Conditions
Type 2 Diabetes
Interventions
HM11260C, liraglutide, Placebo
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 74 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
CA, California
Conditions
Hemophilia A
Interventions
FVIII immuno-assay
Other
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Burlington, Vermont
Conditions
Light-Chain Amyloidosis
Interventions
Ixazomib, Dexamethasone
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
6
States / cities
Boston, Massachusetts • Detroit, Michigan • Rochester, Minnesota + 2 more
Conditions
Diagnostic Imaging
Interventions
BAY1075553
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Multiple Myeloma
Interventions
Belantamab mafodotin, Dexamethasone, Pomalidomide, Bortezomib, Carfilzomib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
12
States / cities
Los Alamitos, California • Torrance, California • Whittier, California + 9 more
Conditions
Multiple Myeloma
Interventions
GSK2110183, Bortezomib, Dexamethasone
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Scottsdale, Arizona • Duarte, California • Atlanta, Georgia + 5 more
Conditions
Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Skin Granular Cell Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Interventions
Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide, Pazopanib, Pazopanib Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
365
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more
Conditions
Multiple Myeloma
Interventions
ASP7487, Velcade, Dexamethasone
Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia • Chicago, Illinois
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Cyclophosphamide, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Smac Mimetic LCL161
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Ventricular Dysfunction, Left
Interventions
LVAD
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Aurora, Colorado